

Senate File 2246 - Introduced

SENATE FILE 2246

BY BOLKCOM

A BILL FOR

1 An Act relating to the regulation of medical cannabidiol
2 under the medical cannabidiol Act, including provisions
3 relating to altering the list of debilitating medical
4 conditions for which the use of medical cannabidiol would be
5 medically beneficial, the form and quantity in which medical
6 cannabidiol may be dispensed, and the definition of medical
7 cannabidiol.

8 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:

1 Section 1. Section 124E.2, subsection 2, paragraph b, Code
2 2018, is amended to read as follows:

3 *b.* Multiple sclerosis ~~with severe and persistent muscle~~
4 ~~spasms.~~

5 Sec. 2. Section 124E.2, subsection 2, Code 2018, is amended
6 by adding the following new paragraphs:

7 NEW PARAGRAPH. *j.* Glaucoma.

8 NEW PARAGRAPH. *k.* Ehlers-Danlos syndrome.

9 NEW PARAGRAPH. *l.* Post-traumatic stress disorder.

10 NEW PARAGRAPH. *m.* Tourette's syndrome.

11 NEW PARAGRAPH. *n.* Muscular dystrophy.

12 NEW PARAGRAPH. *o.* Huntington's disease.

13 NEW PARAGRAPH. *p.* Alzheimer's disease.

14 NEW PARAGRAPH. *q.* Complex regional pain syndrome, types I
15 and II.

16 NEW PARAGRAPH. *r.* Rheumatoid arthritis.

17 NEW PARAGRAPH. *s.* Polyarteritis nodosa.

18 NEW PARAGRAPH. *t.* Any other chronic or debilitating disease
19 or medical condition or its medical treatment approved by the
20 department pursuant to rule.

21 Sec. 3. Section 124E.2, subsection 6, Code 2018, is amended
22 by striking the subsection and inserting in lieu thereof the
23 following:

24 6. "*Medical cannabidiol*" means any pharmaceutical grade
25 cannabinoid used for medicinal purposes pursuant to rules of
26 the board, including tetrahydrocannabinols naturally contained
27 in a plant of the genus *Cannabis* (*Cannabis* plant) as well
28 as synthetic equivalents of the substances contained in the
29 *Cannabis* plant, or in the resinous extractives of such plant,
30 and synthetic substances, derivatives, and their isomers with
31 similar chemical structure and pharmacological activity to
32 those substances contained in the plant, such as the following:

33 *a.* 1 cis or trans tetrahydrocannabinol, and their optical
34 isomers.

35 *b.* 6 cis or trans tetrahydrocannabinol, and their optical

1 isomers.

2 c. 3,4 cis or trans tetrahydrocannabinol, and their optical
3 isomers. (Since nomenclature of these substances is not
4 internationally standardized, compounds of these structures,
5 regardless of numerical designation of atomic positions
6 covered.)

7 d. Nabilone [another name for nabilone: (+-) -
8 trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy
9 -6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one].

10 Sec. 4. Section 124E.5, subsection 4, Code 2018, is amended
11 to read as follows:

12 4. Recommendations made by the medical cannabidiol board
13 pursuant to [subsection 3](#), paragraphs "b" and "e", shall be made
14 to the ~~board of medicine~~ department for consideration, and if
15 approved, shall be adopted by the ~~board of medicine~~ department
16 by rule.

17 Sec. 5. Section 124E.11, subsection 2, paragraph c, Code
18 2018, is amended to read as follows:

c. Establish the form and quantity of medical cannabidiol allowed to be dispensed to a patient or primary caregiver pursuant to [this chapter](#) as appropriate to serve the medical needs of patients with debilitating medical conditions, subject to recommendation by the medical cannabidiol board ~~and approval by the board of medicine.~~

25	EXPLANATION
----	-------------

26 The inclusion of this explanation does not constitute agreement with
27 the explanation's substance by the members of the general assembly.

28 This bill relates to the regulation of medical cannabidiol.
29 The bill adds glaucoma, Ehlers-Danlos syndrome, post-traumatic
30 stress disorder, Tourette's syndrome, muscular dystrophy,
31 Huntington's disease, Alzheimer's disease, complex regional
32 pain syndrome types I and II, rheumatoid arthritis,
33 polyarteritis nodosa, and any other chronic or debilitating
34 disease or medical condition or its medical treatment approved
35 by the department of public health pursuant to rule to the

1 definition of "debilitating medical condition" for which the
2 use of medical cannabidiol would be medically beneficial. The
3 bill also removes the requirement that multiple sclerosis
4 be accompanied by severe and persistent muscle spasms to be
5 considered a debilitating medical condition.

6 The bill alters the definition of medical cannabidiol.
7 The bill requires the medical cannabidiol board to make
8 recommendations regarding the alteration of the list of
9 debilitating medical conditions for which the use of medical
10 cannabidiol would be medically beneficial and the form and
11 quantity in which medical cannabidiol may be dispensed to the
12 department of public health. Current law requires that such
13 recommendations be made to the Iowa board of medicine.